Feature

8 Promo Pitfalls Pharma Compliance Chiefs Need To Know

Law360 (January 22, 2019, 4:53 PM EST) -- The U.S. Food and Drug Administration's increasingly docile enforcement posture toward pharmaceutical advertisements may be emboldening drugmakers to take promotional liberties, a potentially perilous move despite the laid-back oversight.

After falling to historic lows during the last years of the Obama administration, enforcement by the FDA's Office of Prescription Drug Promotion has plunged even further during the Trump administration. The office publicized seven disciplinary letters in 2018 — a decline of more than 85 percent from its recent high of 52 letters in 2010.

Here, experts share eight promotional pitfalls that pharma compliance officers need to know in today's enforcement environment....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS